rosiglitazone has been researched along with Cancer of Pancreas in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Feng, Y; Gao, Y; Li, X; Qian, K; Shen, W; Wang, G; Wang, Z; Xu, X; Yue, L; Zhang, S | 1 |
| Bai, W; Gao, S; Guo, Y; Hao, J; Huang, C; Jiang, W; Liu, J; Wang, H; Wang, X; Xie, Y; Yang, S; Yuan, S; Zhao, K; Zhao, T; Zhou, T | 1 |
| Carson, DD; Engel, BJ | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Herrigel, DJ; Moss, RA | 1 |
| Cao, LQ; Li, Y; Lin, DQ; Zhang, DW | 1 |
| Bai, MH; Liu, XX; Ma, HB; Wang, XJ; Xue, FJ; Xue, XH | 1 |
| Endo, H; Fujita, K; Hosono, K; Iida, H; Ikeda, I; Inamori, M; Kubota, K; Nagashima, Y; Nakagama, H; Nakajima, A; Nakajima, N; Saito, S; Sugiyama, M; Takahashi, H; Tomimoto, A; Wada, K; Yoneda, K | 1 |
| Chen, GS; Ding, GX; Luo, C; Ou, XL; Shao, Y; Sun, WH; Xiao, B; Xu, HC; Xue, YP; Yang, Y; Zhang, Y; Zhao, QS; Zhou, SM | 1 |
| Dong, YW; Wang, XP; Wu, K | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T | 1 |
| Balkwill, FR; Bossard, M; Candido, JB; Cook, N; Emami-Shahri, N; Hagemann, T; Maniati, E; Nedospasov, SA; Tuveson, DA | 1 |
| Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM | 1 |
| Evers, BM; Farrow, B; Hashimoto, K; Iwamura, T; O'Connor, KL | 1 |
| Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E | 1 |
| Chayama, K; Fujimoto, Y; Kawasaki, Y; Kuwada, Y; Sasaki, T; Tsuchida, A | 1 |
2 review(s) available for rosiglitazone and Cancer of Pancreas
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
15 other study(ies) available for rosiglitazone and Cancer of Pancreas
| Article | Year |
|---|---|
The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells.
Topics: Animals; Cell Survival; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; PPAR gamma; Rosiglitazone; Tumor Cells, Cultured; X-Rays | 2020 |
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Topics: Animals; Cohort Studies; Disease Models, Animal; Humans; Hypoglycemic Agents; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, CXCR4; Rosiglitazone; Transcription Factors | 2022 |
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms | 2013 |
Peroxisome proliferator-activated receptor-γ inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN.
Topics: Cell Line, Tumor; Cell Movement; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Pancreatic Neoplasms; PPAR gamma; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones | 2015 |
[Effects of activated PPARgamma on the expression of PTEN gene in pancreatic cancer cells].
Topics: Anilides; Cell Line, Tumor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Pancreatic Neoplasms; PPAR gamma; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2008 |
Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility.
Topics: Animals; Benzamides; Catenins; cdc42 GTP-Binding Protein; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Delta Catenin; Humans; Ligands; Mice; Mice, SCID; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; PPAR gamma; Pyridines; rac1 GTP-Binding Protein; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Xenograft Model Antitumor Assays | 2008 |
Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Topics: Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase Inhibitors; DNA Primers; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Nitrobenzenes; Pancreatic Neoplasms; PPAR gamma; Proliferating Cell Nuclear Antigen; Rosiglitazone; Sulfonamides; Thiazolidinediones | 2009 |
Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
Topics: Animals; Base Sequence; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; PPAR gamma; Prostaglandin D2; Retinoid X Receptor alpha; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazolidinediones; Transplantation, Heterologous; Tretinoin; Vascular Endothelial Growth Factor A | 2009 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, ras; Histones; Homeodomain Proteins; I-kappa B Kinase; Inflammation; Mice; Mice, Inbred C57BL; Neoplasm Proteins; NF-kappa B; Pancreatic Diseases; Pancreatic Neoplasms; Phosphorylation; PPAR gamma; Precancerous Conditions; Protein Processing, Post-Translational; Proto-Oncogene Mas; Receptors, Notch; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factor HES-1; Tumor Necrosis Factor-alpha | 2011 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2013 |
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Topics: Chromans; Humans; Integrins; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Pancreatic Neoplasms; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2003 |
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Male; Matrix Metalloproteinases; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Pioglitazone; Plasminogen Activators; PPAR gamma; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2004 |
Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.
Topics: Antineoplastic Agents; Cell Division; Chromans; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Humans; Pancreatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |